Liver toxicity concerns spike Motif Bio’s iclaprim filing

Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.

The company says the regulator has rejected its marketing application for iclaprim as a treatment for acute bacterial skin and skin structure infections (ABSSSI) as it needs “additional data … to further evaluate the risk for liver toxicity before [it] can be approved.”